Semaglutide in Auto-HSCT
NCT06449625 on ClinicalTrials.gov · last registry update 2024-06-10
A small phase 2 — 40 participants, against a typical 110. Due to report 31 December 2026, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: gastrointestinal mucositis severity. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Klaus Gottlob Müller
- Sponsor type
- Other
- Enrollment
- 40
- Started
- 2024-08-12
- Primary completion
- 2026-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
gastrointestinal mucositis severity
Conditions studied
Intestinal Mucositis · Inflammation · Chemotherapeutic Toxicity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.